Open Label Extension Study of HT-100 in Patients With DMD

Stopped early · Phase 2

Conditions studied: Duchenne Muscular Dystrophy

In brief

This study is designed to provide 6-months continuous dosing with the study medication, called HT-100, on participants who successfully completed the predecessor study (HALO-DMD-01). The main purpose of this study is to assess chronic safety, tolerability, pharmacodynamic activity (testing the drug's effect on DMD) and population pharmacokinetics (measuring how much drug is in the bloodstream) in participants with a broad spectrum of Duchenne muscular dystrophy (DMD).

Key facts

Study ID
NCT01978366
Run by
Processa Pharmaceuticals
People needed
17
Starts
2013-10-01
Expected to finish
2016-04-30
Last updated by the study team
2020-09-03

Who can join

Age: 6 and older, up to 20. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.